Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cholestatic syndromes.

Michael Trauner1, James L Boyer

  • 1Division of Gastroenterology and Hepatology, Department of Internal Medicine, Karl-Franzens University, School of Medicine, Graz, Austria.

Current Opinion in Gastroenterology
|October 13, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Utility of Elastography in Discriminating Stages of Liver Fibrosis and Risk Stratification in Patients With Primary Sclerosing Cholangitis: A Systematic Review.

Journal of magnetic resonance imaging : JMRI·2026
Same author

Long-Term Use of Fenofibrate as Second-Line Therapy in Primary Biliary Cholangitis: A Retrospective Study.

Alimentary pharmacology & therapeutics·2026
Same author

Conjugated bile acid-driven CD14<sup>+</sup>CD16<sup>+</sup> monocyte infiltration promotes cholestatic liver injury by enhancing hepatocyte necroptosis.

JHEP reports : innovation in hepatology·2025
Same author

Liver Lymphatic Dysfunction as a Driver of Fibrosis and Cirrhosis Progression.

bioRxiv : the preprint server for biology·2025
Same author

PPAR agonists for the treatment of cholestatic liver diseases: Over a decade of clinical progress.

Hepatology communications·2024
Same author

PPAR-Mediated Bile Acid Glucuronidation: Therapeutic Targets for the Treatment of Cholestatic Liver Diseases.

Cells·2024
Same journal

Endoscopic techniques to minimize gastroesophageal reflux during peroral endoscopic myotomy.

Current opinion in gastroenterology·2026
Same journal

Postendoscopy esophageal adenocarcinoma and neoplasia: current status and future directions.

Current opinion in gastroenterology·2026
Same journal

The complement system in inflammatory bowel disease: from early observations to emerging frontiers.

Current opinion in gastroenterology·2026
Same journal

Goblet cell-associated antigen passages in health and disease.

Current opinion in gastroenterology·2026
Same journal

Inflammatory bowel diseases 2026: form, function and therapeutic considerations for the epithelial barrier.

Current opinion in gastroenterology·2026
Same journal

Dietary protein as a regulator of colitis and colorectal cancer.

Current opinion in gastroenterology·2026
See all related articles

Understanding bile acid transport and metabolism is key to diagnosing and treating cholestatic liver diseases. New research on ursodeoxycholic acid offers hope for improved therapies for these conditions.

Area of Science:

  • Hepatology and Gastroenterology
  • Molecular Biology
  • Genetics

Background:

  • Cholestatic liver diseases stem from impaired bile acid transport and metabolism.
  • Understanding these processes is crucial for disease pathogenesis and treatment.
  • Genetic mutations in transporter genes are linked to hereditary cholestatic syndromes and gallstone disease.

Purpose of the Study:

  • To elucidate the molecular regulation of bile acid transport and metabolism.
  • To advance the understanding of cholestatic liver disease pathogenesis.
  • To explore novel therapeutic insights for cholestatic liver diseases, particularly concerning ursodeoxycholic acid.

Main Methods:

  • Review of recent molecular and genetic studies.
  • Analysis of research on bile acid transporters.

Related Experiment Videos

  • Examination of clinical studies on primary biliary cirrhosis, drug-induced cholestasis, and cholestasis of pregnancy.

    • Main Results:

    • Insights into molecular regulation provide a basis for understanding cholestatic liver disease pathogenesis.
    • Novel mechanisms of ursodeoxycholic acid action are emerging for treatment.
    • Transporter gene mutations are identified as causes of hereditary cholestatic syndromes and gallstone disease.

    Conclusions:

    • Further research into bile acid transport and metabolism enhances understanding of cholestatic liver diseases.
    • Ursodeoxycholic acid holds promise for improved treatment strategies.
    • Genetic factors play a significant role in the development of cholestatic conditions.